Repeated botulinum toxin injection for idiopathic overactive bladder: will chemodenervation become a long-term...

Area of Science:

• Urology
• Pharmacology

Background:

• Idiopathic overactive bladder (OAB) presents a significant clinical challenge, particularly when refractory to antimuscarinic agents.
• Existing treatments like sacral neuromodulation and augmentation enterocystoplasty address severe OAB but may involve invasive procedures.

Purpose of the Study:

• To review the role and outcomes of repeated botulinum toxin A (BTX-A) injections for idiopathic overactive bladder (OAB).
• To evaluate the safety, efficacy, and feasibility of long-term, repeated BTX-A use in OAB patients.

Main Methods:

• Review of existing literature on BTX-A injections for idiopathic OAB.
• Analysis of studies focusing on repeated administration protocols and patient outcomes.

Main Results:

• BTX-A has emerged as a viable therapeutic option for refractory OAB.
• Repeated injections of BTX-A have shown sustained efficacy and a favorable safety profile in managing OAB symptoms.

Conclusions:

• Repeated BTX-A injections represent an important advancement in managing idiopathic OAB refractory to conventional treatments.
• The safety, efficacy, and ease of delivery support BTX-A as a valuable long-term therapeutic strategy for OAB.